繁體
简体中文
繁體中文

State Street IG公共和私人信貸主動型ETF PRIV 深 滬

等待開盤 11-04 09:30:00 美东时间

24.30

-0.025

-0.10%

华盛通華盛通
立即下載
  • 最 高24.34
  • 今 開24.2903
  • 成交量 1.83万股
  • 最 低 24.2701
  • 昨 收 24.3249
  • 總市值 8.07亿
  • 52周最高 24.9353
  • 市盈率 靜 --
  • 換手率 0.00%
  • 52周最低 23.7105
  • 委 比 0.00%
  • 總股本 3320.00万
  • 歷史最高 24.9353
  • 量 比 1.74
  • 振 幅 0.29%
  • 歷史最低 22.4344
  • 每 手 1
  • 風險率 0.23%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • EyePoint Announces Strategic Prioritization

    EyePoint, Inc. announced strategic adjustments to reduce operating expenses and focus on its late-stage DURAVYU program for diabetic macular edema (DME) after the Phase 3 LUCIA study in wet AMD did not meet its primary endpoint, despite improvements in vision and treatment burden reduction. The company plans to reduce its workforce by approximately 53% and end wet AMD trials early to conserve capital and prioritize DME development. DURAVYU is exp...

    10-19 11:15

  • EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

    EyePoint announced topline results from the LUCIA Phase 3 trial of DURAVYU for wet AMD. While visual improvement was demonstrated, the primary endpoint of statistical non-inferiority in BCVA change vs. aflibercept was not met. Key secondary endpoints were achieved, including a 38% reduction in treatment burden and strong anatomic control. The favorable safety profile was maintained. The DME program remains on track with Phase 3 data expected in Q...

    10-19 11:00

  • Takeda Refines VPRIV Home Infusion Playbook With New EU Survey

    Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clini...

    10-02 00:30

  • Private credit resilience tested as BDC discounts widen

    Wells Fargo Investment Institute is maintaining a constructive stance on private credit (BIZD) (VPC) (HYIN) (PRIV) and direct lending, citing the asset class's resilience through the first half of 202...

    09-09 00:42